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In this issue ofNeuron, Chakrabarty et al. (2015) and Guillot-Sestier et al. (2015) reveal that the anti-inflamma-
tory cytokine IL-10 inhibits Ab clearance by microglia, worsening cognitive decline in mouse models of
Alzheimer’s disease (AD). These studies provide further support that pro-inflammatory signaling is an innate
immune defense mechanism in AD.Alzheimer’s disease (AD) is themost com-
mon cause of dementia worldwide and
its incidence is expected to significantly
increase concomitantly with population
aging. This incurable pathology is asso-
ciated with hyperphosphorylated tau,
neuronal death, and an imbalance be-
tween amyloid beta (Ab) production and
elimination, resulting in the accumulation
of this neurotoxic peptide in the brain of
affected individuals.
Ab is the product of amyloid precursor
protein (APP) cleavage by b- and g-secre-
tases. Released monomeric Ab of various
sizes, with Ab42 and Ab40 being the
most frequent, constitute building blocks
of a dynamic and complex network of
intermediates such as oligomers, fibrils,
and plaques. A plethora of studies
demonstrated that several of these Ab
assemblies induce synaptic damage, ex-
citotoxicity, and neuronal death and, ulti-
mately, cognitive impairments (Benilova
et al., 2012). Inexplicably, most cases of
AD are associated with decreased degra-
dation of Ab (Mawuenyega et al., 2010).
Post-mortem investigations reveal a
strong immune response in AD brains
and epidemiological data support a cen-
tral role for innate immunity in the etiology
of the disease. In line with this, several
experimental studies confirmed the major
involvementofmicrogliaandmonocytes in
this pathology (Prokop et al., 2013).
Although these cells are attracted to Ab
and capable of efficiently internalizing
and degrading it under certain circum-
stances, evidence also suggests that
they exhibit a dysfunctional phenotype in
AD (Orre et al., 2014; Prokop et al.,
2013). This includes reduced phagocy-450 Neuron 85, February 4, 2015 ª2015 Elsetosis and increased secretion of inflam-
matory mediators potentially harmful to
neurons and catalyst of Ab processing.
Aberrant, chronic inflammation has
long been hypothesized to be a driving
force that promotes AD. Nevertheless,
clinical trials with anti-inflammatory
agents have failed to demonstrate bene-
ficial effects on AD, worsening disease
outcomes in some cases. Furthermore,
a number of studies based on genetic
and pharmacologic approaches targeting
the immune system reported conflicting
results in transgenic animal models of
AD. Although inhibition of the innate im-
mune response mostly provoked aggra-
vation of symptoms, moderate activation
of microglia and monocytes frequently
ameliorated AD-like pathology (Prokop
et al., 2013).
Whereas the detrimental effects of pro-
inflammatory pathways have attracted
a lot of attention, the favorable properties
of anti-inflammatory cytokines have been
assumed without extensive investigation.
It is noteworthy that increased risk of
AD in certain populations is associated
with functional polymorphism of Inter-
leukin-10 (IL-10) (Lio et al., 2003), a major
anti-inflammatory cytokine for mono-
nuclear phagocytes such as microglia.
In this issue of Neuron, Chakrabarty
et al. (2015) and Guillot-Sestier et al.
(2015) investigated the role of IL-10 in
a context of cerebral amyloidosis and
elegantly demonstrated its detrimental
effects using various approaches based
on different animal models, cell culture,
and human tissues.
Chakrabarty et al. (2015) first explored
the effects of IL-10 overexpression usingvier Inc.adeno-associated virus (AAV2/1) in two
transgenic (Tg) murine models of AD,
including the TgCRND8 and the Tg2576
variants. These mice exhibit pathological
production of Ab that induces AD-like
features, such as plaque buildups in the
cortical and hippocampal areas, gliosis,
synaptic deficits, and cognitive impair-
ments. The authors report an augmenta-
tion in the concentration of Ab as well as
in the number and the size of insoluble
plaques in mice overexpressing IL-10
compared to the controls. Remarkably,
comparable increase in Ab burden was
reproduced in the Tg2576 mouse model
subjected to similar IL-10 overexpression
strategy. Guillot-Sestier et al. (2015) used
a different approach and hypothesized
that microglia dysfunction in AD, which
prevents proper elimination of Ab, might
be triggered by the endogenous produc-
tion of IL-10. Genetic deletion of IL-10 in
APP/PS1 mice led to significant decline
of the area occupied by Ab plaques in
the cortex and hippocampus. The severity
of cerebral amyloid angiopathy, charac-
terized by the deposition of Ab within the
walls of blood vessels was also reduced
in APP/PS1/IL-10/ mice. Additionally,
the total concentrations of both Ab42 and
Ab40 were drastically lowered by up to
85%. Importantly, the effects observed
in these two studies did not seem to be
caused by changes in Ab processing or
enzymatic degradation, as the main pro-
teins involved in these processes were
not affected.
In the three transgenic lines used, IL-
10 modulated the expression of genes
involved in various inflammatory path-
ways such as acute phase response,
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phagocytosis. Interestingly, Guillot-Sest-
ier et al. (2015) revealed that both Il10r
and Il10 mRNAs were induced in micro-
glia of APP/PS1 mice, suggesting an
autocrine signaling in this pathology. In
APP/PS1 mice devoid of IL-10, common
cellular markers of microglial activation
were appreciably enhanced, implying an
increased activation of microglial cells.
In addition, more microglia were found
in close proximity to Ab plaques in
APP/PS1/IL-10/ mice, indicating also
an increased cell migration. Even more
remarkable, plaques found in APP/PS1/
IL-10/ mice displayed a more diffuse
morphology, suggesting that IL-10-defi-
cient microglia may be more prone to
penetrate and fragment the core of these
deposits. Microglia in APP/PS1/IL-10/
mice contained more encapsulated Ab
and exhibited a larger phagolysosome
volume. In a complementary set of data,
Chakrabarty et al. (2015) demonstrated
that the activation of Signal transducer
and activator of transcription 3 (STAT3)
by IL-10 significantly reduced Ab phago-
cytosis in cultured microglia but had no
effect on astrocytes.
Both groups then sought to identify a
mechanismof action bywhich IL-10 could
compromise Ab phagocytosis by micro-
glia. The role for apolipoprotein E (ApoE),
the most important genetic risk factor
for sporadic AD, was explored because
IL-10 enhanced its transcription in glial
cells and it can potentially inhibit micro-
glial degradation of Ab (Liu et al., 2013).
Remarkably, Tg mice injected with
AAV2/1-IL-10 exhibited nearly 400% in-
crease of ApoE specifically located in
the insoluble protein fraction. These apo-
lipoproteins were in fact highly bound to
Ab deposits and inhibited phagocytosis
by glial cells. In vitro incubation of micro-
glia with Ab and the different human
isoforms of ApoE revealed a significant
isoform-dependent uptake reduction
by ApoE4 and ApoE3 (E4 > E3), while
ApoE2 had no significant impact. This
result is consistent with the relative risk
factors of ApoE isoforms in AD (E4 >
E3 > E2). Importantly, ApoE3-mediated
impairment of Ab uptake was alleviated
in IL-10/ microglia. The link between
IL-10 and ApoE is very interesting and
novel. However, an important factor that
can impactApoE-mediated uptake reduc-tion of Ab is its level of lipidation. Indeed,
whereas highly lipidated ApoE increases
the clearance of Ab, unlipidated ApoE
inhibits microglial degradation of Ab
(Liu et al., 2013). For example, the retinoid
X receptor (RXR) agonist bexarotene pro-
vided great microglial uptake by a mech-
anism dependent on lipidated ApoE
(Cramer et al., 2012). Based on the data
of the two studies presented here, IL-10
likely leads to a detrimental unlipidated
ApoE augmentation, although neither
study addressed this question. To validate
the importance of ApoE in this context, it
would be crucial to compare relative im-
provements of IL-10 deletion in APP/PS1
mice crossed with ApoE-deficient mice
as well as chimeras expressing human
ApoE2, ApoE3, or ApoE4.
Finally, key proteins involved in neu-
ronal activation, neuronal plasticity, and
learning, which are usually affected in
Tg AD mice, were reduced by IL-10. In
agreement with these results, extensive
behavioral assessment revealed that this
anti-inflammatory cytokine precipitated
cognitive impairments normally detected
in these Tg lines. In the case of IL-10
deletion in APP/PS1 mice, it essentially
rescued cognitive functions to levels of
non-Tg mice. Finally, to conclude their
study, Guillot-Sestier et al. (2015) pre-
sented a crucial set of data underlying
the clinical relevance of IL-10 signaling in
AD. Indeed, IL-10Ra, Jak1, pJak1,
STAT3, pSTAT3, as well as SOCS3 were
all significantly increased in the hippo-
campus of AD patients compared to
age-matched control brains.
It is important to mention that most
results observed in APP/PS1/IL-10/
mice could not be recapitulated in hete-
rozygous APP/PS1/IL-10+/ mice. There-
fore, it implies that a beneficial IL-10
blockade in patients would have to be
complete or at least superior to 50%.
Furthermore, while these two papers
mainly focused on Ab phagocytosis, it is
conceivable that the results obtained
could be due to IL-10 having other effects
on microglia (e.g., secretion of trophic
factors and clearance of cell debris) and
even on other cell types.
In conclusion, these complementary
studies reached similar conclusions ex-
ploiting different models of brain amyloid-
osis. On the one hand, Chakrabarty et al.
(2015) showed that overexpression ofNeuron 85IL-10 is clearly detrimental. On the other
hand, Guillot-Sestier et al. (2015) demon-
strated that even endogenous levels of
IL-10 accelerate the pathology. Their find-
ings suggest that in healthy individuals
or in early phases of AD, activated micro-
glia are efficient to migrate and infiltrate
Ab deposits and phagocyte fibrillar Ab
(Figure 1). As the disease progresses,
microglia become progressively dysfunc-
tional/senescent, displaying decreased
activation, migration, and phagocytosis.
IL-10 produced by these cells seems to
participate in such phenomena by inhibit-
ing these cellular functions in a paracrine
fashion through activation of Stat3. In
parallel, IL-10 stimulates the secretion of
ApoE from microglia and astrocytes,
which bind to Ab and hinder its phago-
cytosis. The inadequate removal of Ab
eventually leads to synaptic toxicity and
memory impairments.
While IL-10 has a negative effect on
microglial Ab phagocytosis, it is unclear
whether circulating monocytes can be
affected by IL-10 overexpression or dele-
tion. Importantly, similarly to microglia,
monocytes from AD patients also exhibit
a dysfunctional/senescent profile charac-
terized by impaired phagocytosis and
being more prone to apoptosis (Fiala
et al., 2005). Recently, it was shown that
the patrolling Ly6Clow subset of mono-
cytes can scavenge vascular Ab, which
reduces the parenchymal Ab load (Mi-
chaud et al., 2013a). Moreover, mono-
cytes are a more accessible therapeutic
target compared to microglia. Therefore,
the exact role of IL-10 in monocytes
should be addressed using bone marrow
chimeric mice strategies.
The two teams previously demon-
strated that the anti-inflammatory cyto-
kines IL-4 and TGF-b also exacerbated
AD-like symptoms through inhibition of
microglia and monocytes (Chakrabarty
et al., 2012; Town et al., 2008). Moreover,
deletion of the inhibitory receptor
CX3CR1 found on microglia activates
these cells and stimulates the elimination
of Ab (Liu et al., 2010). Globally, these
data indicate that inhibition of the innate
immune system seems detrimental in
AD. In fact, inhibited and dysfunctional
microglia could trigger a vicious circle
leading to ‘‘frustrated microglia.’’ Anti-
inflammatory cytokines such as IL-10
could prevent proper clearance of Ab by, February 4, 2015 ª2015 Elsevier Inc. 451
Figure 1. Proposed Model by which IL-10 Negatively Affects Ab Clearance by Microglia
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tosis, and migration. At the same time,
without efficient removal of Ab, these cells
could respond by the pathological pro-
duction of pro-inflammatory mediators,
which can in turn promote amyloidogene-
sis. In this regard, various pharmacolog-
ical stimulations of innate immunity can
be harnessed to specifically and effec-
tively clear Ab with positive outcomes on
synaptic integrity and cognitive perfor-
mances (Prokop et al., 2013). Moreover,
gene deletion of innate immune receptors
that bind Ab, such as the Toll-like recep-
tors (TLRs) and downstream signaling452 Neuron 85, February 4, 2015 ª2015 Elsepathways, often exacerbated the pathol-
ogy. However, to benefit optimally from
microglia and monocytes, phagocytosis
must be stimulated without a sustained
excessive inflammatory response, such
as with the TLR4 ligand MPL (Michaud
et al., 2013b) and M-CSF (Boissonneault
et al., 2009).
In light of these results, we have
to appreciate that inflammation in the
context of AD is not exclusively detri-
mental or beneficial but has to be fine-
tuned and needs further investigation. If
the conclusion of these two studies holds
true in the more complex human pathol-vier Inc.ogy, IL-10 could be a promising therapeu-
tic target to block in AD.
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